At the beginning of this decade, the average survival of patients with metastatic melanoma was 7 months and the 5-year rate was 3%. Thanks to the introduction of new drugs such as Vemurafenib and Ipilimumab, the survival rate rose to 20% and now, with PD-1 and CTLA-4 antibodies and combined targeted treatments based on BRAF and MEK inhibitors, survival is 40-50% . Prof. Garbe explains why a 5-year rate of 60-70% could be achieved in the near future.
At the beginning of this decade, the average survival of patients with metastatic melanoma was 7 months and the 5-year rate was 3%. Thanks to the introduction of new drugs such as Vemurafenib and Ipilimumab, the survival rate rose to 20% and now, with PD-1 and CTLA-4 antibodies and combined targeted treatments based on BRAF and MEK inhibitors, survival is 40-50% . Prof. Garbe explains why a 5-year rate of 60-70% could be achieved in the near future.
WORLD CONGRESS OF DERMATOLOGY 2019 - MILAN
Metastatic Melanoma: 5-year survival rates may soon reach 60%
Nutrition's effects on inflammatory skin diseases
Immunotherapy in advanced squamous cell carcinoma
Artificial Intelligence in detection of coutaneous melanoma
Psoriasi moderata: puntare alla remissione completa della malattia
Psoriasis: correlation of extent of skin disease with QOL
Treatment success and failure in psoriasis: clinical implications
Rosacea, nuovi criteri diagnostici per il corretto trattamento
Toward a better understanding of cutan. vascular stains
A successful surgical- pharmac. treatment of primary lymphedema
Immunoterapia efficace nel carcinoma spinocellulare
Keloids: latest updates on etiology and pathogenesis
The multimodality approach to facial rejuvenation
Clinical standards in the management of atopic dermatitis
